Close Menu

Paul Stoffels, company group chairman for Global R&D Pharmaceuticals at Johnson & Johnson, has a guest blog at CNBC about how "recent advances in science, genomics technologies, biomarkers, and drug development" have coalesced to offer the potential for personalized medicine. Using HIV drug development as an example, Stoffels makes the case that relying on diagnostic expertise throughout the process led not only to more targeted treatment, but also helped the pharma make better drugs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.